company background image
AAJ0 logo

Perspective Therapeutics DB:AAJ0 Stock Report

Last Price

€2.30

Market Cap

€168.2m

7D

-0.9%

1Y

-78.3%

Updated

07 Mar, 2025

Data

Company Financials +

Perspective Therapeutics, Inc.

DB:AAJ0 Stock Report

Market Cap: €168.2m

AAJ0 Stock Overview

Develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. More details

AAJ0 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

My Notes

Capture your thoughts, links and company narrative

Perspective Therapeutics, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Perspective Therapeutics
Historical stock prices
Current Share PriceUS$2.30
52 Week HighUS$17.20
52 Week LowUS$2.02
Beta1.26
1 Month Change-23.84%
3 Month Change-31.95%
1 Year Change-78.30%
3 Year Change-25.32%
5 Year Changen/a
Change since IPO-82.96%

Recent News & Updates

Recent updates

Shareholder Returns

AAJ0DE BiotechsDE Market
7D-0.9%-3.7%3.3%
1Y-78.3%-17.9%18.1%

Return vs Industry: AAJ0 underperformed the German Biotechs industry which returned -17.9% over the past year.

Return vs Market: AAJ0 underperformed the German Market which returned 18.1% over the past year.

Price Volatility

Is AAJ0's price volatile compared to industry and market?
AAJ0 volatility
AAJ0 Average Weekly Movement14.1%
Biotechs Industry Average Movement9.6%
Market Average Movement5.2%
10% most volatile stocks in DE Market11.5%
10% least volatile stocks in DE Market2.8%

Stable Share Price: AAJ0's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: AAJ0's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
1998118Thijs Spoorwww.perspectivetherapeutics.com

Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans.

Perspective Therapeutics, Inc. Fundamentals Summary

How do Perspective Therapeutics's earnings and revenue compare to its market cap?
AAJ0 fundamental statistics
Market cap€168.23m
Earnings (TTM)-€53.20m
Revenue (TTM)€1.44m

113.3x

P/S Ratio

-3.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
AAJ0 income statement (TTM)
RevenueUS$1.56m
Cost of RevenueUS$0
Gross ProfitUS$1.56m
Other ExpensesUS$59.27m
Earnings-US$57.71m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

Mar 26, 2025

Earnings per share (EPS)-0.85
Gross Margin100.00%
Net Profit Margin-3,706.62%
Debt/Equity Ratio0.5%

How did AAJ0 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/03/07 03:28
End of Day Share Price 2025/03/07 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Perspective Therapeutics, Inc. is covered by 13 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Edward WooAscendiant Capital Markets LLC
Alec StranahanBofA Global Research
Yuan ZhiB. Riley Securities, Inc.